China’s newly revised “Drug Administration Law” was approved and implemented by the National People’s Congress (NPC) Standing Committee.
Takehomes: The newly revised “Drug Administration Law” encourages drug development and innovation in five major areas, and gives priority to reviewing and approving these medicines. A risk control mechanism for halting clinical trials at any time has been established. The Law introduces an extended clinical trial clause for the drugs used for seriously life-threatening disease.…
